Literature DB >> 17276409

Structurally novel histamine H3 receptor antagonists GSK207040 and GSK334429 improve scopolamine-induced memory impairment and capsaicin-induced secondary allodynia in rats.

Andrew D Medhurst1, Michael A Briggs, Gordon Bruton, Andrew R Calver, Iain Chessell, Barry Crook, John B Davis, Robert P Davis, Andrew G Foley, Teresa Heslop, Warren D Hirst, Stephen J Medhurst, Sandrine Ociepka, Alison Ray, Ciaran M Regan, Becky Sargent, Joanne Schogger, Tania O Stean, Brenda K Trail, Neil Upton, Trevor White, Barry Orlek, David M Wilson.   

Abstract

GSK207040 (5-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-N-methyl-2-pyrazinecarboxamide) and GSK334429 (1-(1-methylethyl)-4-({1-[6-(trifluoromethyl)-3-pyridinyl]-4-piperidinyl}carbonyl)hexahydro-1H-1,4-diazepine) are novel and selective non-imidazole histamine H(3) receptor antagonists from distinct chemical series with high affinity for human (pK(i)=9.67+/-0.06 and 9.49+/-0.09, respectively) and rat (pK(i)=9.08+/-0.16 and 9.12+/-0.14, respectively) H(3) receptors expressed in cerebral cortex. At the human recombinant H(3) receptor, GSK207040 and GSK334429 were potent functional antagonists (pA(2)=9.26+/-0.04 and 8.84+/-0.04, respectively versus H(3) agonist-induced changes in cAMP) and exhibited inverse agonist properties (pIC(50)=9.20+/-0.36 and 8.59+/-0.04 versus basal GTPgammaS binding). Following oral administration, GSK207040 and GSK334429 potently inhibited cortical ex vivo [(3)H]-R-alpha-methylhistamine binding (ED(50)=0.03 and 0.35 mg/kg, respectively). Functional antagonism of central H(3) receptors was demonstrated by blockade of R-alpha-methylhistamine-induced dipsogenia in rats (ID(50)=0.02 and 0.11 mg/kg p.o. for GSK207040 and GSK334429, respectively). In more pathophysiologically relevant pharmacodynamic models, GSK207040 (0.1, 0.3, 1 and 3mg/kg p.o.) and GSK334429 (0.3, 1 and 3mg/kg p.o.) significantly reversed amnesia induced by the cholinergic antagonist scopolamine in a passive avoidance paradigm. In addition, GSK207040 (0.1, 0.3 and 1mg/kg p.o.) and GSK334429 (3 and 10mg/kg p.o.) significantly reversed capsaicin-induced reductions in paw withdrawal threshold, suggesting for the first time that blockade of H(3) receptors may be able to reduce tactile allodynia. Novel H(3) receptor antagonists such as GSK207040 and GSK334429 may therefore have therapeutic potential not only in dementia but also in neuropathic pain.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17276409     DOI: 10.1016/j.bcp.2007.01.007

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  17 in total

Review 1.  The histamine H3 receptor: an attractive target for the treatment of cognitive disorders.

Authors:  T A Esbenshade; K E Browman; R S Bitner; M Strakhova; M D Cowart; J D Brioni
Journal:  Br J Pharmacol       Date:  2008-05-12       Impact factor: 8.739

Review 2.  Alzheimer's disease and age-related memory decline (preclinical).

Authors:  Alvin V Terry; Patrick M Callahan; Brandon Hall; Scott J Webster
Journal:  Pharmacol Biochem Behav       Date:  2011-02-24       Impact factor: 3.533

3.  Overdose of the histamine H₃ inverse agonist pitolisant increases thermal pain thresholds.

Authors:  Dong Dong Zhang; Marco Sisignano; Claus Dieter Schuh; Kerstin Sander; Holger Stark; Klaus Scholich
Journal:  Inflamm Res       Date:  2012-07-21       Impact factor: 4.575

Review 4.  H3 receptors and pain modulation: peripheral, spinal, and brain interactions.

Authors:  Lindsay B Hough; Frank L Rice
Journal:  J Pharmacol Exp Ther       Date:  2010-09-23       Impact factor: 4.030

Review 5.  Histamine H3 receptors and its antagonism as a novel mechanism for antipsychotic effect: a current preclinical & clinical perspective.

Authors:  Danish Mahmood
Journal:  Int J Health Sci (Qassim)       Date:  2016-10

6.  Histamine H3 and H4 receptor ligands modify vascular histamine levels in normal and arthritic large blood vessels in vivo.

Authors:  Konstantinos Kyriakidis; Evangelia Zampeli; Marina Palaiologou; Dina Tiniakos; Ekaterini Tiligada
Journal:  Inflammation       Date:  2015       Impact factor: 4.092

7.  Preclinical investigations into the antipsychotic potential of the novel histamine H3 receptor antagonist GSK207040.

Authors:  Eric Southam; Jackie Cilia; Jane E Gartlon; Marie L Woolley; Laurent P Lacroix; Carol A Jennings; Jane E Cluderay; Charlie Reavill; Claire Rourke; David M Wilson; Lee A Dawson; Andrew D Medhurst; Declan N C Jones
Journal:  Psychopharmacology (Berl)       Date:  2008-09-03       Impact factor: 4.530

8.  Use of the H3 receptor antagonist radioligand [3H]-A-349821 to reveal in vivo receptor occupancy of cognition enhancing H3 receptor antagonists.

Authors:  T R Miller; I Milicic; J Bauch; J Du; B Surber; K E Browman; K Marsh; M Cowart; J D Brioni; T A Esbenshade
Journal:  Br J Pharmacol       Date:  2009-05       Impact factor: 8.739

Review 9.  Histaminergic mechanisms for modulation of memory systems.

Authors:  Cristiano André Köhler; Weber Cláudio da Silva; Fernando Benetti; Juliana Sartori Bonini
Journal:  Neural Plast       Date:  2011-08-18       Impact factor: 3.599

10.  The Effect of Subchronic Dosing of Ciproxifan and Clobenpropit on Dopamine and Histamine Levels in Rats.

Authors:  D Mahmood; K K Pillai; R Khanam; K Jahan; D Goswami; M Akhtar
Journal:  J Exp Neurosci       Date:  2015-08-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.